Despite recent advances in the treatment of myelodysplastic syndrome (MDS), single-agent clinical effects remain unsatisfactory, and decitabine monotherapy is also associated with a relatively low rate of complete remission. To study the combined effects and mechanism of decitabine (DAC) and arsenic trioxide (ATO) on the human myelodysplastic cell line SKM-1,we used the MTS assay and CalcuSyn software to determine the cytotoxicity and potential synergistic effects, respectively. Furthermore, we determined apoptosis and measured the mRNA expression level of two genes that are considered main regulators of the apoptosis process. The results showed that DAC and/or ATO can inhibit the proliferation of SKM-1 cells and demonstrated significant synergy between the two agents (CI < 1). Additionally, combination of 2.5 μmol/L DAC and 5 μmol/L ATO led to a significantly higher apoptosis rate and more significantly decreased the Bcl2/Bax ratio than either compound alone ( < 0.001). Based on the observations of this study, we suggest that combined administration of these two drugs might be considered a novel therapeutic regimen for treating MDS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074963PMC
http://dx.doi.org/10.1007/s12288-015-0632-0DOI Listing

Publication Analysis

Top Keywords

synergistic effects
8
arsenic trioxide
8
trioxide ato
8
ato human
8
human myelodysplastic
8
myelodysplastic syndrome
8
effects decitabine
4
decitabine combined
4
combined arsenic
4
syndrome cell
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!